baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

CENCORA DL-,01/ US03073E1055 /

6/14/2024 8:04:27 AM	Chg. +0.45	Volume	Bid9:59:59 PM	Ask9:59:59 PM	Market Capitalization	Dividend Y.	P/E Ratio
214.60EUR	+0.21%	0 Turnover: 0.00	-Bid Size: -	-Ask Size: -	43.32 bill.EUR	-	-

GlobeNewswire 5/29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

GlobeNewswire 5/28 Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizuma...

GlobeNewswire 5/15 Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Cor...

GlobeNewswire 5/13 Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...

GlobeNewswire 5/9 Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 202...

GlobeNewswire 5/2 Outlook Therapeutics® to Present at the Retina World Congress 2024

GlobeNewswire 4/29 Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Show...

GlobeNewswire 4/17 2024 ICCC Program Provides Free Training, Education, and Mentorship to Small Business Owners

GlobeNewswire 4/15 Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

GlobeNewswire 3/22 Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for ...

GlobeNewswire 3/18 Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

GlobeNewswire 3/18 Parexel Announces CEO Succession Plan

GlobeNewswire 3/12 Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

GlobeNewswire 2/14 Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corp...

GlobeNewswire 1/23 Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-...

GlobeNewswire 1/2 Coherus Announces U.S. Launch of LOQTORZI™

GlobeNewswire 12/22/2023 Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinica...

GlobeNewswire 12/19/2023 Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ...

GlobeNewswire 12/6/2023 Outlook Therapeutics® Announces Strategic Organizational Realignment

GlobeNewswire 11/27/2023 Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path For...

GlobeNewswire 11/14/2023 Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior V...

GlobeNewswire 11/2/2023 Outlook Therapeutics® Provides Update on Type A Meetings with FDA

GlobeNewswire 11/1/2023 Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (IN...

Newsfile Corp 10/26/2023 Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694

GlobeNewswire 9/29/2023 Outlook Therapeutics® Requests Type A Meeting With FDA

CENCORA DL-,01/ US03073E1055 /

If you wish to receive reply to your feedback, please provide your email address.